Purple Biotech Presents Strong Preclinical Data for IM1240, Validating CAPTN-3 Platform for Clinical Advancement
PPBT sits 15% above its 52-week low of $1.75 on elevated volume (36× avg).
Summary
Purple Biotech reported new preclinical data for its lead oncology candidate, IM1240, demonstrating improved safety and efficacy in non-human primate and patient-derived studies, supporting its progression to human clinical trials in 2027.
Key Events · Product Development and Regulatory · PPBT
-
CAPTN-3 Masking Strategy Validated
Non-human primate (NHP) toxicology study confirmed the CAPTN-3 masking strategy for IM1240, showing an 8-fold longer half-life and 16-fold greater systemic exposure compared to a non-capped variant.
-
Improved Safety Profile
IM1240 demonstrated a markedly improved cytokine-release safety profile in NHPs, effectively mitigating peripheral T-cell activation and preventing systemic cytokine release, a key challenge for T-cell engagers.
-
Anti-Tumor Activity in Resistant Cancers
IM1240 showed anti-tumor activity across PD-1- and chemotherapy-resistant patient-derived tumor samples in head and neck, bladder, and lung cancers, with the NKG2A arm identified as a key contributor.
-
Advancement to Clinical Study
The preclinical data supports the planned advancement of IM1240 toward a first-in-human clinical study in 2027.
Analysis · PPBT · Life Sciences
Purple Biotech announced significant positive preclinical data for its lead CAPTN-3 program, IM1240, at EACR 2026. The data from non-human primate toxicology studies validate the CAPTN-3 masking strategy, showing an 8-fold longer half-life, 16-fold greater exposure, and a markedly improved safety profile by mitigating cytokine release. This is a critical de-risking step for advancing the candidate. Furthermore, IM1240 demonstrated anti-tumor activity in patient-derived samples from PD-1 and chemotherapy-resistant cancers, highlighting its potential in difficult-to-treat indications. These results strongly support the company's plan to initiate a first-in-human clinical study in 2027, which is a major milestone for a clinical-stage oncology company.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.7% of the 1072 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.61%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PPBT was trading at $2.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $1.75 to $29.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.